In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Zydus Lifescience Ltd reported Total revenue for Q4 FY23 of ₹5,011 Crore, up from ₹3,806 Crore year on year depicting a growth of 32%.
- Total Expenses for Q4 FY23 of ₹3,755 Crore up, from ₹3,088 Crore year on year, a growth of 22%.
- Consolidated Net Profit of ₹358 Crore, down 21% from ₹453 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹2.93, down 24% from ₹3.88 in the same quarter of the previous year.